MTOR and B-cell chronic lymphocytic leukemia: In addition, the expression of Cyclin A, Cyclin D2 and MCL1 was reduced in human CLL models when treated with mTOR inhibitors, reaching significance when combined with IB (Fig. 7B, C & Supplementary Fig. 14).